1. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005; 208:207–227.
Article
2. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996; 312:1254–1259.
Article
3. Osteoporosis . review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int. 1998; 8:Suppl 4. S1–88.
4. Royal College of Physicians of London. Osteoporosis: Clinical Guidelines for Prevention and Treatment. London: Royal College of Physicians of London;1999.
5. Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dent Res. 2006; 85:584–595.
Article
6. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest. 2003; 111:1651–1664.
Article
7. Gallo D, Zannoni GF, Apollonio P, Martinelli E, Ferlini C, Passetti G, Riva A, Morazzoni P, Bombardelli E, Scambia G. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause. 2005; 12:589–600.
Article
8. Mennini T, Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci. 2004; 75:1021–1027.
Article
9. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther. 2000; 22:411–419.
Article
10. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000; 15:61–68.
Article
11. You MK, Rhuy J, Jeong KS, Bang MA, Kim MS, Kim HA. Effect of St. John's Wort (Hypericum perforatum) on obesity, lipid metabolism and uterine epithelial proliferation in ovariectomized rats. Nutr Res Pract. 2014; 8:292–296.
Article
12. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2:595–610.
Article
13. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28:2–17.
Article
14. Cho YS, Jung WK, Kim JA, Choi IL, Kim SK. Beneficial effects of fucoidan on osteoblastic MG-63 cell differentiation. Food Chem. 2009; 116:990–994.
Article
15. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009; 88:1–17.
Article
16. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000; 141:3478–3484.
Article
17. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancerinduced bone diseases. Cancer Metastasis Rev. 2006; 25:541–549.
Article
18. Kim J, Um SJ, Woo J, Kim JY, Kim HA, Jang KH, Kang SA, Lim BO, Kang I, Choue RW, Cho Y. Comparative effect of seeds of Rhynchosia volubilis and soybean on MG-63 human osteoblastic cell proliferation and estrogenicity. Life Sci. 2005; 78:30–40.
Article
19. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol. 1999; 13:1672–1685.
Article
20. Watkins MP, Norris JY, Grimston SK, Zhang X, Phipps RJ, Ebetino FH, Civitelli R. Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice. Bone. 2012; 51:787–794.
Article
21. Hodgkinson A, Aaron JE, Horsman A, McLachlan MS, Nrodin BE. Effect of oophorectomy and calcium deprivation on bone mass in the rat. Clin Sci Mol Med. 1978; 54:439–446.
Article
22. Wronski TJ, Lowry PL, Walsh CC, Ignaszewski LA. Skeletal alterations in ovariectomized rats. Calcif Tissue Int. 1985; 37:324–328.
Article
23. Wronski TJ, Dann LM, Scott KS, Cintrón M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int. 1989; 45:360–366.
Article
24. Faienza MF, Ventura A, Marzano F, Cavallo L. Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol. 2013; 2013:575936.
Article
25. Srivastava AK, Bhattacharyya S, Castillo G, Miyakoshi N, Mohan S, Baylink DJ. Development and evaluation of C-telopeptide enzyme-linked immunoassay for measurement of bone resorption in mouse serum. Bone. 2000; 27:529–533.
Article
26. Srivastava AK, Bhattacharyya S, Li X, Mohan S, Baylink DJ. Circadian and longitudinal variation of serum C-telopeptide, osteocalcin, and skeletal alkaline phosphatase in C3H/HeJ mice. Bone. 2001; 29:361–367.
Article
27. Shan PF, Wu XP, Zhang H, Luo XH, Cao XZ, Xie H, Liu SP, Pi YZ, Fang TY, Liu H, Chen ZH, Zhong N, Liao EY. Age-related changes of serum bone alkaline phosphatase and cross-linked C-telopeptides of type I collagen and the relationship with bone mineral density in Chinese women. Clin Chim Acta. 2006; 366:233–238.
Article